Search

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

Black innovators contribution to health & wellness throughout the years

Read about the many contributions Black innovators have made throughout history and how they continue to shape scientific discoveries today.

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

From garbage to garden - Recycling organic waste to contribute to a healthier planet

Words of Health and Hope

Click here to hear from our patients, who have expressed to us in beautifully written thank you notes for our BI Cares Patient Assistance Program.

Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials

Economist Impact Report: Rethinking Mental Health Care

Prescription digital therapeutics and mental health care

Partnering-Mental-Health-Disorders_0.pdf

Partnering-Mental-Health-Disorders.pdf

Bringing Value to the Healthcare Community

Our fundamental mission is to make the lives of patients better.

Human Health Innovation

Pipeline

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.

FDA accepts Jardiance sNDA for T2D in children 10 and older

The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes

Update on sNDA for fibrosing ILD in children and adolescents

Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)

FDA accepts sNDA for children/adolescents with fibrosing ILD

U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease

Interdisciplinary approach to CKM care

Explore the global impact of Cardiovascular- Kidney- Metabolic (CKM) syndrome, and the need for an integrated approach to manage these interconnected conditions. Insights from experts at Boehringer Ingelheim and George Washington University.

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

BI Launches Vaccine to Protect Poultry | Boehringer Ingelheim US

Read more on the Boehringer Ingelheim launched Animal Health vaccine, aimed at protecting poultry from three different diseases.

Vetmedica Inc to Sell Vaccine Portfolio | Boehringer Ingelheim US

Read more on Boehringer Ingelheim Vetmedica Inc. entering into an agreement to sell feline, canine and rabies vaccines to Elanco Animal Health in the USA.

Our Curiosity Never Stops | Boehringer Ingelheim US

Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.

Where to meet us | Animal Health Boehringer Ingelheim US

Find out where to meet the BD&L team virtually or in person at the next conference or event. Submit your opportunity to our BD&L team here.

Animal Health

Companion Animals, Horse Pets and Equines

Schizophrenia in real life: Stories of resilience and hope

Discover the reality of life with schizophrenia through the stories of four people who are breaking down the stigma of living with a serious mental illness.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

Black innovators contribution to health & wellness throughout the years

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

From garbage to garden - Recycling organic waste to contribute to a healthier planet

Words of Health and Hope

Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials

Economist Impact Report: Rethinking Mental Health Care

Prescription digital therapeutics and mental health care

Partnering-Mental-Health-Disorders_0.pdf

Partnering-Mental-Health-Disorders.pdf

Bringing Value to the Healthcare Community

Human Health Innovation

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

FDA accepts Jardiance sNDA for T2D in children 10 and older

Update on sNDA for fibrosing ILD in children and adolescents

FDA accepts sNDA for children/adolescents with fibrosing ILD

Interdisciplinary approach to CKM care

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

BI Launches Vaccine to Protect Poultry | Boehringer Ingelheim US

Vetmedica Inc to Sell Vaccine Portfolio | Boehringer Ingelheim US

Our Curiosity Never Stops | Boehringer Ingelheim US

Where to meet us | Animal Health Boehringer Ingelheim US

Animal Health

Schizophrenia in real life: Stories of resilience and hope